TSR 042

Drug Profile

TSR 042

Alternative Names: ANB 011; Anti-PD-1 mAb; Anti-PD-1 monospecific antagonist antibody; TSR-042

Latest Information Update: 26 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AnaptysBio
  • Developer TESARO
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action PDCD 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Endometrial cancer; Solid tumours

Most Recent Events

  • 07 Nov 2017 TESARO plans a phase III trial for Non small cell lung cancer (Combination therapy) in 2H 2018
  • 07 Nov 2017 TESARO plans a phase III trial for Ovarian cancer (First-line treatment, Combination therapy) in 1H 2018
  • 12 Oct 2017 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Combination therapy, Inoperable/Unresectable, Second-line therapy or greater) in USA (Parenteral) (NCT03307785)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top